Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07012642 · ClinicalTrials.gov registry record · Early Phase 1
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
A Early Phase 1 study of Lymphedema, sponsored by Advanced Reconstructive Surgery Alliance.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 110
- Enrollment target
- 2
- Study locations
NCT07012642: Recruiting Early Phase 1 study of Lymphedema, sponsored by Advanced Reconstructive Surgery Alliance.
NCT07012642 is a Early Phase 1 study of Lymphedema that is actively recruiting participants, run by Advanced Reconstructive Surgery Alliance. The registered enrollment target is 110 participants, below the 9,297-participant average among 34 other Lymphedema trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07012642, a Early Phase 1 study of Lymphedema, is actively recruiting participants, sponsored by Advanced Reconstructive Surgery Alliance.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 110 participants
- Enrollment target
- 2
- Study locations
Study Summary
Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby addressing a critical gap in literature and potentially offering a new treatment option.
Primary Outcome
Lymphedema Life Impact Scale
Conditions Studied
Interventions
- DRUG GLP-1 Receptor Agonists
Study Locations (2)
New Jersey
- River Center - Red Bank
- 260 Old Hook Rd Suite 304 - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2027-04-09 |
| Phase | Early Phase 1 |
What NCT07012642 shows while recruiting
NCT07012642 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 9,297-participant average among 34 other Lymphedema trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Lymphedema appearing as the primary indexed condition, and to 1 intervention - of which GLP-1 Receptor Agonists is the first listed.
NCT07012642 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT07012642 about?
NCT07012642 is a clinical study titled "Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema". Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of...
What is the current status of trial NCT07012642?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 110 participants. The study started on 2025-04-09. Estimated completion is 2027-04-09.
What conditions does trial NCT07012642 study?
This clinical trial studies the following conditions: Lymphedema.
What interventions are being tested in trial NCT07012642?
The interventions under investigation include: GLP-1 Receptor Agonists (DRUG).
Who is sponsoring clinical trial NCT07012642?
This trial is sponsored by Advanced Reconstructive Surgery Alliance, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07012642 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07012642's enrollment target sits among peer trials
110 17th of 34 higher than 18 of 34 other Lymphedema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphedema Surveillance Study
RECRUITING
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.
RECRUITING · Phase 2
-
Prospective Screening for Breast Cancer-related Lymphedema
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI